Delivery Order SPE2DB22D3011-SPE2DB24FQ2CL

Award Date 6/20/24
Potential Completion Date 6/21/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to supply the pharmaceutical product Dupixent 300 mg/2 ml pen (2 ml). The contract, valued at $37,165.78, has a firm fixed price and is scheduled for completion by September 16, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued up to $999,999,999 through December...
This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order valued at $4,228.32 awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the supply of the prescription medication Dupixent 300 mg/2 ml pen, with a period of performance ending on August 2, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a $6,946.30 Firm Fixed Price Delivery Order placed by the Defense Logistics Agency (DLA) Troop Support Medical. The award is for the supply of the prescription drug Dupixent 300 mg/2 ml pen, with a completion date of September 27, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the prescription drug Dupixent (300 mg/2 ml pen, 2 ml). The contract is a Firm Fixed Price Delivery Order with a ceiling value of $1,652.36 and an ultimate completion date of July 18, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up...
This federal contract award, valued at $9,454.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which covers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific Delivery...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of the medication Dupixent (200 mg/1.14 ml pen) to the Defense Logistics Agency (DLA). The contract has a total ceiling value of $1,918.07 and runs through June 2024. It is a delivery order contract with a firm fixed price pricing type. There is no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of the prescription drug Dupixent 300 mg/2 mL pen to the Defense Logistics Agency (DLA) Troop Support Medical. The contract is a delivery order with a firm fixed price ceiling of $24,241.76 and an ultimate completion date of September 17, 2024. As a large indefinite delivery contract (IDC) holder with DLA Troop Support Medical, valued up to $999,999,999 through December 2025,...
This federal contract award, valued at $13,418.85, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a Delivery Order under the DLA's Indefinite Delivery Contract (IDC) valued at $999,999,999, covers the supply of Dupixent 300 mg/2 ml pen (2 ml) to support military healthcare programs. This contract does not have a set-aside designation, indicating open competition....
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $24,188.15 for the supply of Dupixent 300 mg/2 ml pen medication. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of April 19, 2023. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger $999,999,999 Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $24,270.25, is for the delivery of the prescription drug Dupixent 300 mg/2 ml pens. This is a Firm Fixed Price contract with a completion date of August 13, 2024. The contract is not set aside for any specific business type. As a key supplier of medical commodities to the U.S. government, Amerisourcebergen has been awarded...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB24FQ2CL
    Delivery Order

This federal contract award, valued at $14,684.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the prescription drug Dupixent (300 mg/2 ml pen, 2 ml) to support U.S. government medical programs. The contract is a firm-fixed-price delivery order with a completion date of June 21, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation.

Generated 9/19/24, 9:29 AM